|
2024
|
Invention
|
Method of treating hormonal disorders using injectable leuprolide.
A method and system for treat... |
|
|
Invention
|
Pharmaceutical compositions having a selected release duration.
The present invention provides f... |
|
|
Invention
|
Long-acting injectable (lai) composition of cariprazine. A sustained release pharmaceutical compo... |
|
2023
|
Invention
|
Depot compositions for vesicular monoamine transporter 2 (vmat2) inhibitors. The present inventio... |
|
|
Invention
|
Depot compositions for vesicular monoamine transporter 2 (vmat2) inhbitors.
The present inventio... |
|
|
Invention
|
Pharmaceutical compositions having a selected release duration. The present invention provides fo... |
|
|
Invention
|
Crystalline (+)-tetrabenazine.
The present application relates to crystal forms of (+)-tetrabena... |
|
|
Invention
|
Crystalline (+)-tetrabenazine. The present application relates to crystal forms of (+)-tetrabenaz... |
|
2022
|
Invention
|
Polymeric compositions for sustained delivery of vmat2 inhibitors.
The present application relat... |
|
|
Invention
|
Polymer depot compositions for sustained release delivery of vmat2 inhibitors. The present applic... |
|
|
Invention
|
Methods of manufacturing injectable sustained release formulations.
The present application prov... |
|
|
Invention
|
Methods of manufacturing injectable sustained release formulations. The present application provi... |
|
|
Invention
|
Use of mmp inhibitors for treating acute respiratory distress syndrome. Methods of treating acute... |
|
|
Invention
|
Safe administration of mmp-12 inhibitor. Methods of safely administrating a matrix metalloprotein... |
|
2021
|
Invention
|
Pharmaceutical composition with improved stability.
The present invention provides an injectable... |
|
|
P/S
|
pharmaceutical preparations for the treatment of sex hormone-related diseases and disorders |
|
2020
|
Invention
|
Matrix metalloproteinase (mmp) inhibitors and methods of use thereof. Hydantoin based compounds u... |
|
|
P/S
|
Pharmaceutical preparations, namely, leuprolide mesylate injectable emulsion for the treatment of... |
|
|
P/S
|
Pharmaceutical preparations, namely, leuprolide mesylate injectable suspension; |
|
2019
|
Invention
|
Matrix metalloproteinase (mmp) inhibitors and methods of use thereof.
Hydantoin based compounds ... |
|
|
Invention
|
Pharmaceutical compositions with enhanced stability. The present invention provides for a stabili... |
|
|
P/S
|
Pharmaceutical preparations, namely, leuprolide mesylate injectable suspension used only for the ... |
|
|
P/S
|
Pharmaceutical preparations, namely, leuprolide mesylate injectable suspension. |
|
2018
|
Invention
|
Esters of dihydrotetrabenazine. The present invention relates to a compound of formula (I) includ... |
|
|
P/S
|
pharmaceutical preparations, namely, leuprolide mesylate injectable suspension. |
|
|
P/S
|
pharmaceutical preparations, namely, leuprolide mesylate injectable suspension |
|
|
Invention
|
Pharmaceutical composition for sustained release delivery of buprenorphine. The present invention... |
|
2017
|
Invention
|
Methods of making pharmaceutical compositions with enhanced stability. The present invention prov... |
|
2015
|
Invention
|
Pharmaceutical composition with improved stability. The present invention provides an injectable ... |
|
|
Invention
|
Lactate-based polymer controlled release drug delivery compositions with improved stability.
|
|
2012
|
Invention
|
Pharmaceutical compositions for sustained release delivery of peptides. The present invention pro... |
|
2009
|
Invention
|
Non-polymeric compositions for controlled drug delivery. The present invention provides a novel l... |
|
|
Invention
|
Composition for sustained release delivery of proteins or peptides.
The present invention provid... |
|
2007
|
Invention
|
Pharmaceutical compositions with enhanced stability.
The present invention provides for a stabil... |
|
2005
|
Invention
|
5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of mac... |
|
|
Invention
|
Pharmaceutical compositions for controlled release delivery of biologically active compounds. The... |
